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Background
IC is one of the most important extra-articular complica-
tions of JIA. However, little information exists on the time
of onset of IC during the disease course.
Objective
To evaluate the frequency of IC onset over time in JIA
patients who developed this complication.
Methods
1050 JIA patients seen between 1985 and 2007 were iden-
tified. 172 patients (16.4%) had IC. 6 patients with
enthesitis-related arthritis with acute IC, 4 patients who
developed IC before arthritis onset and 2 patients in
whom date of IC onset was unknown were excluded. Of
the remaining 160 patients, 108 (67.5%) had oligoarthri-
tis, 36 (22.5%) RF-negative polyarthritis, 9 (5.6%) undif-
ferentiated arthritis, 6 (3.8%) psoriatic arthritis, 1 (0.6%)
systemic arthritis. Of the 158 patients who had ANA
tested, 144 (91.1%) were positive (≥ 1:160), 8 (5.1%)
low-positive (≤ 1:80) or doubtful, 6 (3.8%) negative.
Results
The cumulative proportion of patients who developed IC
over time is shown in figure 1 and table 1.
Conclusion
Of 160 patients who had IC, half developed this compli-
cation in the first year, 2/3 in the first 2 years, 4/5 in the
first 3 years, and only 5.6% after 7 years. This suggests that
risk of IC onset is greatest in the first 3 years of disease and
that the optimal time for reducing the frequency of oph-
thalmologic visits is 7 years after onset.
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Table 1: 
Time (years) 0–1 1–2 2–3 3–4 4–5 5–6 6–7 7–8 8–14
Cumulative% 48.1 68.1 78.7 84.3 87.5 91.9 94.4 96.9 100Page 1 of 2
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